NCT07005414View on ClinicalTrials.gov

Efficacy of Bumetanide in Children With Autism Spectrum Disorder Guided by Peripheral Blood Biomarkers and Machine Learning Models

PHASE2RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

June 4, 2025

Primary Completion Date

May 30, 2026

Study Completion Date

May 30, 2026

Conditions
Autism Spectrum Disorder
Interventions
DRUG

Bumetanide

Participants will receive bumetanide (0.5mg bid) for a period of three months.

BEHAVIORAL

Treatment as usual (TAU)

Participants will undergo treatment as usual, such as behavioral interventions

Trial Locations (1)

200092

RECRUITING

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Fei Li

OTHER

NCT07005414 - Efficacy of Bumetanide in Children With Autism Spectrum Disorder Guided by Peripheral Blood Biomarkers and Machine Learning Models | Biotech Hunter | Biotech Hunter